FDA
-
-
-
-
-
-
-
Caribou Biosciences Inc. (CRBU) PT Raised to $4 at Leerink Partners
-
-
-
-
-
-
-
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
-
-
-
-
-
-
-
Caribou Bioscience, Inc (CRBU) Appoints Terri Laufer to its Board
-
-
-
-
-
-
-
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Caribou Bioscience (CRBU) Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
-
-
-
-
-
-
-
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

